We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Low Dose Aspirin Studied With the AggreGuide

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01603966
First Posted: May 23, 2012
Last Update Posted: July 17, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Edward R. Teitel, M.D., Aggredyne, Inc.
  Purpose
This study is to determine whether the AggreGuide platelet aggregometer can discern the effect of low dose aspirin on subjects platelet aggregation using arachidonic acid as the agonist.

Condition
Platelet Aggregation

Study Type: Observational
Study Design: Observational Model: Case-Crossover
Time Perspective: Prospective
Official Title: Low Dose Aspirin Study With the AggreGuide

Resource links provided by NLM:


Further study details as provided by Edward R. Teitel, M.D., Aggredyne, Inc.:

Biospecimen Retention:   None Retained
whole blood

Enrollment: 13
Study Start Date: April 2012
Study Completion Date: June 2012
Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
community sample
Criteria

Inclusion Criteria:

  • adults

Exclusion Criteria:

  • aspirin contraindications
  • anticoagulants
  • aspirin past week
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01603966


Locations
United States, Texas
Aggredyne, Inc.
Houston, Texas, United States, 77099
Sponsors and Collaborators
Edward R. Teitel, M.D.
Investigators
Principal Investigator: Edward R. Teitel, MD Aggredyne, Inc.
  More Information

Responsible Party: Edward R. Teitel, M.D., CEO, Aggredyne, Inc.
ClinicalTrials.gov Identifier: NCT01603966     History of Changes
Other Study ID Numbers: Val-030
First Submitted: May 21, 2012
First Posted: May 23, 2012
Last Update Posted: July 17, 2012
Last Verified: July 2012

Keywords provided by Edward R. Teitel, M.D., Aggredyne, Inc.:
platelet
aggregation
aspirin
inhibition
reactivity

Additional relevant MeSH terms:
Aspirin
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Platelet Aggregation Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Antipyretics